Hemant Surgical completes Lifesenz acquisition

Hemant Surgical Industries Limited has completed the acquisition of Lifesenz Cancer Research Labs Private Limited for ₹19,99,80,000 to expand its presence in the healthcare and cancer diagnostic support segment. The acquisition, which was approved by the board on May 27, 2026, was finalized on June 01, 2026, making Lifesenz a subsidiary of the company with effect from the same date. The deal was structured as a related party transaction, as existing shareholders and directors of the target entity are also promoters, directors, or shareholders of Hemant Surgical Industries.

The transaction involved the purchase of 6,666 equity shares representing 66.66% of the paid-up equity share capital of Lifesenz Cancer Research Labs. The consideration of ₹19,99,80,000 was paid in cash, based on a valuation report from a Registered Valuer. The company stated that the transaction was undertaken at arm's length and was subject to conditions precedent specified in the Share Purchase Agreement, which have now been satisfied.

Lifesenz Cancer Research Labs, incorporated on February 28, 2022, operates in Mumbai, Maharashtra, and is engaged in assisting clinicians and cancer patients by providing predicted therapy solutions. The entity belongs to the healthcare industry, specifically cancer research and diagnostic support services. No governmental or regulatory approvals were required for the acquisition.

The financial size of the target entity for F.Y. 24-25 indicates a turnover of ₹56.75 Lakhs, a Profit After Tax (PAT) of ₹(74.76) Lakhs, and a net worth of ₹(221.84) Lakhs. The acquisition is intended to strengthen Hemant Surgical Industries' capabilities in the cancer diagnostic support market.

Particulars	Details
Name of Target Entity	Lifesenz Cancer Research Labs Private Limited
Cost of Acquisition	₹19,99,80,000
Percentage Acquired	66.66%
Shares Acquired	6,666 Equity Shares
Consideration Type	Cash
Target Turnover (F.Y. 24-25)	₹56.75 Lakhs
Target PAT (F.Y. 24-25)	₹(74.76) Lakhs
Target Net Worth (F.Y. 24-25)	₹(221.84) Lakhs
Completion Date	June 01, 2026

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	+2.15%	-7.54%	+29.98%	+280.14%	+109.94%

Hemant Surgical Industries has allotted 6,49,600 shares to Singularity Equity Fund 1, associated with Madhusudan Kela, following the conversion of warrants. The allotment represents a 5% stake in the company, and upon completion of this transaction, Singularity Equity Fund 1's cumulative shareholding in Hemant Surgical Industries has increased to 6.9%.

Warrant Conversion and Share Allotment Details

The allotment was executed through the conversion of warrants held by Singularity Equity Fund 1. The key details of the transaction are summarised below:

Parameter:	Details
Shares Allotted:	6,49,600
Stake Represented:	5%
Allottee:	Singularity Equity Fund 1 (Madhusudan Kela)
Mode of Allotment:	Warrant Conversion
Post-Allotment Shareholding:	6.9%

Shareholding Impact

Following the allotment of 6,49,600 shares equivalent to a 5% stake, Singularity Equity Fund 1's total holding in Hemant Surgical Industries now stands at 6.9%. This transaction reflects the exercise of warrants previously issued to the fund, resulting in a meaningful increase in its ownership position within the company.